Your browser doesn't support javascript.
loading
Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation.
Bankova, Andriyana K; Pasin, Chloé; Huang, Alice; Cicin-Sain, Caroline; Epp, Selina; Audige, Annette; Mueller, Nicolas J; Nilsson, Jakob; Vilinovszki, Oliver; Nair, Gayathri; Wolfensberger, Nathan; Hockl, Philipp; Schanz, Urs; Trkola, Alexandra; Kouyos, Roger; Hasse, Barbara; Zinkernagel, Annelies S; Manz, Markus G; Abela, Irene A; Müller, Antonia M S.
Afiliación
  • Bankova AK; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Pasin C; Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
  • Huang A; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zürich, Zürich, Switzerland.
  • Cicin-Sain C; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Epp S; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Audige A; Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
  • Mueller NJ; Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
  • Nilsson J; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zürich, Zürich, Switzerland.
  • Vilinovszki O; Department of Immunology, University Hospital Zürich, Zürich, Switzerland.
  • Nair G; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Wolfensberger N; Department of Internal Medicine, University Hospital Zürich, Zürich, Switzerland.
  • Hockl P; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Schanz U; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Trkola A; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Kouyos R; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Hasse B; Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
  • Zinkernagel AS; Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
  • Manz MG; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zürich, Zürich, Switzerland.
  • Abela IA; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zürich, Zürich, Switzerland.
  • Müller AMS; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zürich, Zürich, Switzerland.
Br J Haematol ; 201(1): 58-63, 2023 04.
Article en En | MEDLINE | ID: mdl-36382698
Allogeneic haematopoietic cell transplantation (allo-HCT) recipients show impaired antibody (Ab) response to a standard two-dose vaccination against severe acute respiratory syndrome coronavirus-2 and currently a third dose is recommended as part of the primary vaccination regimen. By assessing Ab titres 1 month after a third mRNA vaccine dose in 74 allo-HCT recipients we show sufficient neutralisation activity in 77% of the patients. Discontinuation of immunosuppression before the third vaccine led to serological responses in 50% of low responders to two vaccinations. Identifying factors that might contribute to better vaccine responses in allo-HCT recipients is critical to optimise current vaccination strategies.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / COVID-19 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Br J Haematol Año: 2023 Tipo del documento: Article País de afiliación: Suiza
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / COVID-19 Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Br J Haematol Año: 2023 Tipo del documento: Article País de afiliación: Suiza